Recently, World famous periodical Science publishes a supplementary issue on Chinese precision medicine and cancer immunotherapy, in which a dozen of Chinese academicians and experts jointly wrote to look both back and ahead in terms of Chinaˊs basic research and clinical progress in this field. An article, with Prof. Zhang Yi, Dean of Biological Cell Therapy Center of No.1 Hospital Affiliated to ZZU and Prof. Han Weidong, Dean of Institute of Molecular Immunology of PLA General Hospital as the corresponding authors, made an in-depth study about the rise and prospect of CAR-T Cell Therapy in China.

It argues that there are various ways to control and eliminate cancer cells, including tumor vaccine, chemotherapy, radiotherapy and tyrosine kinase inhibitor etc. The progress of basic research brought about obviously better effects of malignant tumor treatment. At present, Checkpoint inhibitors such as PD-1/PD-L1 McAb and genetically modified T cells such as CAR-T cell therapy have got preferable curative effects in the clinical application of treating cancers. Immunotherapy has gradually come to the forefront of tumor treatment.(translator Song Gencheng)